Brown Advisory Inc. Has $51.31 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Brown Advisory Inc. reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 88.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 124,101 shares of the company's stock after selling 967,797 shares during the period. Brown Advisory Inc. owned about 0.15% of IDEXX Laboratories worth $51,308,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in IDXX. Geode Capital Management LLC increased its holdings in IDEXX Laboratories by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock valued at $948,279,000 after purchasing an additional 37,734 shares during the period. Bamco Inc. NY grew its position in shares of IDEXX Laboratories by 4.3% in the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock valued at $829,163,000 after buying an additional 82,264 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of IDEXX Laboratories by 2.5% in the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock valued at $675,259,000 after buying an additional 34,305 shares during the period. Invesco Ltd. raised its position in shares of IDEXX Laboratories by 6.8% during the fourth quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock worth $479,999,000 after acquiring an additional 74,324 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $412,258,000. 87.84% of the stock is owned by institutional investors.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the company's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Trading Up 0.1 %

IDXX opened at $471.90 on Monday. The company has a market cap of $38.24 billion, a P/E ratio of 44.23, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. The company has a fifty day moving average price of $419.26 and a two-hundred day moving average price of $428.06. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $548.88.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm's revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.71 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on IDXX. Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Piper Sandler increased their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a report on Monday, April 14th. Morgan Stanley cut their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Finally, StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, April 12th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $523.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.